Recognition of cisplatin adducts by cellular proteins

Rosenberg, 1965, Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode, Nature, 205, 698, 10.1038/205698a0

Rosenberg, 1967, The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes, J. Biol. Chem., 242, 1347, 10.1016/S0021-9258(18)96186-7

Howle, 1970, Cis-dichlorodiammineplatinum(II): persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo, Biochem. Pharmacol., 19, 2757, 10.1016/0006-2952(70)90102-4

Rosenberg, 1969, Platinum compounds: a new class of potent antitumour agents, Nature, 222, 385, 10.1038/222385a0

Kociba, 1970, Inhibition of Dunning ascitic leukemia and Walker 256 carcinosarcoma with cis-diamminedichloroplatinum (NSC-119875), Cancer Chemother. Rep., 54, 325

Welsch, 1971, Growth inhibition of rat mammary carcinoma induced by cis-platinumdiamminodichloride(II), J. Natl. Cancer Inst., 47, 1071

E.J. Feuer, L.M. Brown, R.S. Kaplan, in: B.A. Miller, L.A.G. Ries, B.F. Hankey, C.L. Kosary, A. Harras, S.S. Devesa, B.K. Edwards (Eds.), SEER Cancer Statistics Review: 1973–1990, National Cancer Institute, Bethesda, MD, 1993, pp. XXIV.1–XXIV.13.

Beck, 1973, Effect of cis-platinum(II)diamminodichloride on wild type and deoxyribonucleic acid repair-deficient mutants of Escherichia coli, J. Bact., 116, 1247, 10.1128/JB.116.3.1247-1252.1973

Konishi, 1981, Effects of anticancer platinum compounds on Escherichia coli strains with normal and defective DNA repair capacity, Gann, 72, 627

Alazard, 1982, Mechanism of toxicity of platinum(II) compounds in repair-deficient strains of Escherichia coli, Mutat. Res., 93, 327, 10.1016/0027-5107(82)90148-8

Beck, 1985, Reactions of the Uvr(A)BC excision nuclease with DNA damaged by diamminedichloroplatinum(II), Nucl. Acids Res., 13, 7395, 10.1093/nar/13.20.7395

Fram, 1986, Studies on mutagenesis and repair induced by platinum analogs, Mutat. Res., 173, 13, 10.1016/0165-7992(86)90004-7

Popoff, 1987, Repair of plasmid DNA damaged in vitro with cis- or trans-diamminedichloroplatinum(II) in Escherichia coli, Mutat. Res., 183, 129

Fraval, 1978, Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteus, Mutat. Res., 51, 121, 10.1016/0027-5107(78)90014-3

Poll, 1984, Host-cell reactivation of cis-diamminedichloroplatinum(II)-treated SV40 DNA in normal human, Fanconi anaemia and xeroderma pigmentosum fibroblasts, Mutat. Res., 132, 181

Dijt, 1988, Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts, Cancer Res., 48, 6058

Reed, 1986, Quantitation of cis-diamminedichloroplatinum(II) (cisplatin)–DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy, J. Clin. Invest., 77, 545, 10.1172/JCI112335

Akaboshi, 1992, The number of platinum atoms binding to DNA, RNA and protein molecules of HeLa cells treated with cisplatin at its mean lethal concentration, Jpn. J. Cancer Res., 83, 522, 10.1111/j.1349-7006.1992.tb01959.x

Pascoe, 1974, Interactions between mammalian cell DNA and inorganic platinum compounds(I), Biochem. Pharmacol., 23, 1345, 10.1016/0006-2952(74)90354-2

Pinto, 1985, Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA, Bioschim. Biophys. Acta, 780, 167

Bruhn, 1990, Biological processing of DNA modified by platinum compounds, Prog. Inorg. Chem., 38, 477, 10.1002/9780470166390.ch8

Bancroft, 1990, 195Pt NMR kinetic and mechanistic studies of cis- and trans-diamminedichloroplatinum(II) binding to DNA, J. Am. Chem. Soc., 112, 6860, 10.1021/ja00175a020

Johnson, 1980, Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA, Chem. Biol. Interact., 30, 151, 10.1016/0009-2797(80)90122-2

Eastman, 1983, Characterization of the adducts produced in DNA be cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II), Biochemistry, 22, 3927, 10.1021/bi00285a031

Eastman, 1985, Interstrand cross-links and sequence specificity in the reaction of cis-dichloro(ethylenediamine)platinum(II) with DNA, Biochemistry, 24, 5027, 10.1021/bi00340a011

Fichtinger-Schepman, 1987, Cis-diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II), Cancer Res., 47, 3000

Fichtinger-Schepman, 1985, Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation, Biochemistry, 24, 707, 10.1021/bi00324a025

Plooy, 1985, The quantitative detection of various Pt–DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques, Carcinogenesis, 6, 561, 10.1093/carcin/6.4.561

Eastman, 1987, Interaction of trans-diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione, Biochemistry, 26, 3303, 10.1021/bi00386a009

Eastman, 1988, Characterization of bifunctional adducts produced in DNA by trans-diamminedichloroplatinum(II), Chem. Biol. Interact., 67, 71, 10.1016/0009-2797(88)90087-7

Brabec, 1993, DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues, Proc. Natl. Acad. Sci. U.S.A., 90, 5345, 10.1073/pnas.90.11.5345

Rice, 1988, The major adduct of the antitumor drug cis-diamminedichloroplatinum(II) with DNA bends the duplex by ⪢40° toward the major groove, Proc. Natl. Acad. Sci. U.S.A., 85, 4158, 10.1073/pnas.85.12.4158

Anin, 1990, Distortions induced in double-stranded oligonucleotides by the binding of cis- or trans-diamminedichloroplatinum(II) to the d(GTG) sequence, Nucl. Acids Res., 18, 4395, 10.1093/nar/18.15.4395

Bellon, 1990, Bending studies of DNA site-specifically modified by cisplatin, trans-diamminedichloroplatinum(II) and cis-[Pt(NH3)2(N3-cytosine)Cl]+, Biophys. Chem., 35, 179, 10.1016/0301-4622(90)80007-T

Schwartz, 1989, Conformation of DNA modified at a d(GG) or a d(AG) site by the antitumor drug cis-diamminedichloroplatinum(II), Biochemistry, 28, 7975, 10.1021/bi00446a001

Malinge, 1994, Base sequence-independent distortions induced by interstrand cross-links in cis-diamminedichloroplatinum(II)-modified DNA, Nucl. Acids Res., 22, 3834, 10.1093/nar/22.19.3834

Bellon, 1991, DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II), Biochemistry, 30, 8026, 10.1021/bi00246a021

Takahara, 1996, Crystal structure of the anticancer drug cisplatin bound to duplex DNA, J. Am. Chem. Soc., 118, 12309, 10.1021/ja9625079

Takahara, 1995, Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin, Nature, 377, 649, 10.1038/377649a0

Gelasco, 1998, NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin, Biochemistry, 37, 9230, 10.1021/bi973176v

Yang, 1995, Structure and isomerization of an intrastrand cisplatin-cross-linked octamer DNA duplex by NMR analysis, Biochemistry, 34, 12912, 10.1021/bi00039a054

Fouchet, 1997, Structure of a nonanucleotide duplex cross-linked by cisplatin at an ApG sequence, J. Biol. Inorg. Chem., 2, 83, 10.1007/s007750050109

Corda, 1992, RNA polymerases react differently at d(ApG) and d(GpG) adducts in DNA modified by cis-diamminedichloroplatinum(II), Biochemistry, 31, 1904, 10.1021/bi00122a002

Comess, 1992, Replication inhibition and translation synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts, Biochemistry, 31, 3975, 10.1021/bi00131a013

Teuben, 1999, Solution structure of a DNA duplex containing a cis-diammineplatinum(II) 1,3-d(GTG) intrastrand cross-link, a major adduct in cells treated with the anticancer drug carboplatin, Biochemistry, 38, 12305, 10.1021/bi9904757

van Garderen, 1994, The solution structure of a DNA duplex containing the cis-Pt(NH3)2[d(-GTG-)-N7(G), N7(G)] adduct, as determined with high-field NMR and molecular mechanics/dynamics, Eur. J. Biochem., 225, 1169, 10.1111/j.1432-1033.1994.1169b.x

Huang, 1995, Solution structure of a cisplatin-induced DNA interstrand cross-link, Science, 270, 1842, 10.1126/science.270.5243.1842

Paquet, 1996, NMR solution structure of a DNA docamer containing an interstrand cross-link of the antitumor drug cis-diamminedichloroplatinum(II), J. Biomolec. Struct. Dynamics, 14, 67, 10.1080/07391102.1996.10508930

Coste, 1999, Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site, Nucl. Acids Res., 27, 1837, 10.1093/nar/27.8.1837

Paquet, 1999, NMR solution structure of a DNA dodecamer containing a transplatin interstrand GN7–CN3 cross-link, Nucl. Acids Res., 27, 4261, 10.1093/nar/27.21.4261

Grosschedl, 1994, HMG domain proteins: architectural elements in the assembly of nucleoprotein structures, Trends Genet., 10, 94, 10.1016/0168-9525(94)90232-1

Pil, 1992, Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin, Science, 256, 234, 10.1126/science.1566071

Toney, 1989, Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II), Proc. Natl. Acad. Sci. U.S.A., 86, 8328, 10.1073/pnas.86.21.8328

Donahue, 1990, Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin, Biochemistry, 29, 5872, 10.1021/bi00476a032

Bruhn, 1992, Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin, Proc. Natl. Acad. Sci. U.S.A., 89, 2307, 10.1073/pnas.89.6.2307

Bruhn, 1993, Isolation and characterization of cDNA clones encoding the Drosophila homolog of the HMG-box SSRP family that recognizes specific DNA structures, Nucl. Acids Res., 21, 1643, 10.1093/nar/21.7.1643

Hughes, 1992, Purification of nuclear proteins that bind to cisplatin-damaged DNA, J. Biol. Chem., 267, 13520, 10.1016/S0021-9258(18)42242-9

Billings, 1992, Characterization of high mobility group protein binding to cisplatin-damaged DNA, Biochem. Biophys. Res. Commun., 188, 1286, 10.1016/0006-291X(92)91371-V

Turchi, 1996, Cisplatin–DNA binding specificity of calf high-mobility group 1 protein, Biochemistry, 35, 2992, 10.1021/bi951843j

Pil, 1992, Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin, Science, 256, 234, 10.1126/science.1566071

Churchill, 1995, HMG-D is an architecture-specific protein that preferentially binds to DNA containing the dinucleotide TG, EMBO J., 14, 1264, 10.1002/j.1460-2075.1995.tb07110.x

Fleck, 1998, The high mobility group domain protein Cmb1 of Schizosaccharomyces pombe binds to cytosines in base mismatches and opposite chemically altered guanines, J. Biol. Chem., 273, 30398, 10.1074/jbc.273.46.30398

Treiber, 1994, Cisplatin–DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor), Proc. Natl. Acad. Sci. U.S.A., 91, 5672, 10.1073/pnas.91.12.5672

Chow, 1994, HMG domain proteins induce sharp bends in cisplatin-modified DNA, Biochemistry, 33, 15124, 10.1021/bi00254a023

Brown, 1993, I×r1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin, Science, 261, 603, 10.1126/science.8342024

McA’Nulty, 1996, Binding of I×r1, a yeast HMG-domain protein, to cisplatin–DNA adducts in vitro and in vivo, Biochemistry, 35, 6089, 10.1021/bi952877u

Ohndorf, 1997, Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin–DNA adducts, Biochemistry, 36, 14807, 10.1021/bi9717643

Trimmer, 1998, Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities, Biochemistry, 37, 352, 10.1021/bi971675q

Dunham, 1997, DNA sequence context and protein composition modulate HMG-domain protein recognition of cisplatin-modified DNA, Biochemistry, 36, 11428, 10.1021/bi9709452

Jamieson, 2000, Stopped-flow fluorescence studies of HMG-domain protein binding to cisplatin-modified DNA, Biochemistry, 39, 8426, 10.1021/bi000342h

Love, 1995, Structural basis for DNA bending by the architectural transcription factor LEF-1, Nature, 376, 791, 10.1038/376791a0

Werner, 1995, NMR spectroscopic analysis of the DNA conformation induced by the human testis determining factor SRY, Biochemistry, 34, 11998, 10.1021/bi00037a042

Werner, 1995, Molecular basis of human 46X, Y sex reversal revealed from the three-dimensional solution structure of the human SRY–DNA complex, Cell, 81, 705, 10.1016/0092-8674(95)90532-4

Allain, 1999, Solution structure of the HMG protein NHP6A and its interaction with DNA reveals the structural determinants for non-sequence-specific binding, EMBO J., 18, 2563, 10.1093/emboj/18.9.2563

Peters, 1995, An SRY mutation causing human sex reversal resolves a general mechanism of structure-specific DNA recognition: application to the four-way DNA junction, Biochemistry, 34, 4569, 10.1021/bi00014a009

Ohndorf, 1999, Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins, Nature, 399, 708, 10.1038/21460

Kasparkova, 1995, Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans-isomer by DNA-binding proteins, Biochemistry, 34, 12379, 10.1021/bi00038a035

Barrett, 1998, Crystal structure of a G:T/U mismatch-specific DNA glycosylase: mismatch recognition by complementary-strand interactions, Cell, 92, 117, 10.1016/S0092-8674(00)80904-6

Lau, 1998, Crystal structure of a human alkylbase-DNA repair enzyme complexed to DNA: mechanisms for nucleotide flipping and base excision, Cell, 95, 249, 10.1016/S0092-8674(00)81755-9

Zhai, 1998, Cisplatin–DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor, Biochemistry, 37, 16307, 10.1021/bi981708h

Jordan, 1998, Cisplatin inhibits synthesis of ribosomal RNA in vivo, Nucl. Acids Res., 26, 2831, 10.1093/nar/26.12.2831

Huang, 1994, HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease, Proc. Natl. Acad. Sci. U.S.A., 91, 10394, 10.1073/pnas.91.22.10394

Zamble, 1996, Repair of cisplatin–DNA adducts by the mammalian excision nuclease, Biochemistry, 35, 10004, 10.1021/bi960453+

Patrick, 1998, Human replication protein A preferentially binds cisplatin-damaged duplex DNA in vitro, Biochemistry, 37, 8808, 10.1021/bi9730590

Li, 1997, Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro, Cancer Res., 57, 1487

He, 2000, Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin, Proc. Natl. Acad. Sci. U.S.A., 97, 5768, 10.1073/pnas.100108697

McA’Nulty, 1996, The HMG-domain protein I×r1 blocks excision repair of cisplatin–DNA adducts in yeast, Mutat. Res., 362, 75, 10.1016/0921-8777(95)00037-2

Boulikas, 1996, DNA lesion-recognizing proteins and the p53 connection, Anticancer Res., 16, 225

Yaneva, 1997, The major chromatin protein histone H1 binds preferentially to cis-platinum-damaged DNA, Proc. Natl. Acad. Sci. U.S.A., 94, 13448, 10.1073/pnas.94.25.13448

Kim, 1993, Co-crystal structure of TBP recognizing the minor groove of a TATA element, Nature, 365, 520, 10.1038/365520a0

Kim, 1993, Crystal structure of a yeast TBP/TATA-box complex, Nature, 365, 512, 10.1038/365512a0

Nikolov, 1996, Crystal structure of a human TATA box-binding protein/TATA element complex, Proc. Natl. Acad. Sci. U.S.A., 93, 4862, 10.1073/pnas.93.10.4862

Vichi, 1997, Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP, EMBO J., 16, 7444, 10.1093/emboj/16.24.7444

Coin, 1998, TATA binding protein discriminates between different lesions on DNA, resulting in a transcription decrease, Mol. Cell Biol., 18, 3907, 10.1128/MCB.18.7.3907

Cohen, 2000, Enhanced binding of the TATA-binding protein to TATA boxes containing flanking cisplatin 1,2-cross-links, Biochemistry, 39, 8259, 10.1021/bi0004495

Massaad-Massade, 2000, A single d(GpG) cisplatin adduct on the estrogen response element decreases the binding of the estrogen receptor, FEBS Lett., 466, 49, 10.1016/S0014-5793(99)01755-X

Ohga, 1998, Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene, J. Biol. Chem., 273, 5997, 10.1074/jbc.273.11.5997

Ohga, 1996, Role of the human Y-box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light, Cancer Res., 56, 4224

Ise, 1999, Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen, Cancer Res., 59, 342

Vande, 1998, Evidence for dinucleotide flipping by DNA photolyase, J. Biol. Chem., 273, 20276, 10.1074/jbc.273.32.20276

Sancar, 1984, Escherichia coli DNA photolyase stimulates Uvr(A)BC excision nuclease in vitro, Proc. Natl. Acad. Sci. U.S.A., 81, 7397, 10.1073/pnas.81.23.7397

Ozer, 1995, The other function of DNA photolyase: stimulation of excision repair of chemical damage to DNA, Biochemistry, 34, 15886, 10.1021/bi00049a002

van Noort, 1999, DNA bending by photolyase in specific and non-specific complexes studied by atomic force microscopy, Nucl. Acids Res., 27, 3875, 10.1093/nar/27.19.3875

Fox, 1994, A novel role for DNA photolyase: binding to DNA damaged by drugs is associated with enhanced cytotoxicity in Saccharomyces cerevisiae, Mol. Cell Biol., 14, 8071, 10.1128/MCB.14.12.8071

Patterson, 1989, Evidence that xeroderma pigmentosum cells from complementation group E are deficient in a homolog of yeast photolyase, Mol. Cell Biol., 9, 5105, 10.1128/MCB.9.11.5105

Chu, 1988, Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA, Science, 242, 564, 10.1126/science.3175673

Payne, 1994, Xeroderma pigmentosum group E binding factor recognizes a broad spectrum of DNA damage, Mutat. Res., 310, 89, 10.1016/0027-5107(94)90012-4

Vaisman, 1995, Induction of UV-damage recognition protein by cisplatin treatment, Biochemistry, 34, 105, 10.1021/bi00001a013

Chu, 1990, Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA, Proc. Natl. Acad. Sci. U.S.A., 87, 3324, 10.1073/pnas.87.9.3324

Keeney, 1994, Correction of the DNA repair defect in xeroderma pigmentosum group E by injection of a DNA damage-binding protein, Proc. Natl. Acad. Sci. U.S.A., 91, 4053, 10.1073/pnas.91.9.4053

Rapic Otrin, 1998, Relationship of the xeroderma pigmentosum group E DNA repair defect to the chromatin and DNA binding proteins UV-DDB and replication protein A, Mol. Cell Biol., 18, 3182, 10.1128/MCB.18.6.3182

Jones, 1993, Preferential binding of the xeroderma pigmentosum group A complementing protein to damaged DNA, Biochemistry, 32, 12096, 10.1021/bi00096a021

Asahina, 1994, The XPA protein is a zinc metalloprotein with an ability to recognize various kinds of DNA damage, Mutat. Res., 315, 229, 10.1016/0921-8777(94)90034-5

Kuraoka, 1996, Identification of a damaged-DNA binding domain of the XPA protein, Mutat. Res., 362, 87, 10.1016/0921-8777(95)00038-0

Schweizer, 1999, Photocrosslinking locates a binding site for the large subunit of human replication protein A to the damaged strand of cisplatin-modified DNA, Nucl. Acids Res., 27, 3183, 10.1093/nar/27.15.3183

Dabholkar, 1994, Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy, J. Clin. Invest., 94, 703, 10.1172/JCI117388

Ferry, 1996, Expression of nucleotide excision repair genes in CDDP-sensitive and resistant human ovarian cancer cell lines, Proc. Am. Assoc. Cancer Res., 37, 365

Nagai, 1995, Enhancement of damage-specific DNA binding of XPA by interaction with the ERCC1 DNA repair protein, Biochem. Biophys. Res. Commun., 211, 960, 10.1006/bbrc.1995.1905

Codegoni, 1997, Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer, Gynecol. Oncol., 65, 130, 10.1006/gyno.1996.4609

Metzger, 1996, ERCC1 expression correlates with response of primary gastric cancer to cisplatin-based chemotherapy, Proc. Am. Cancer Res., 37, 197

Dabholkar, 1992, ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients, J. Natl. Cancer Inst., 84, 1512, 10.1093/jnci/84.19.1512

Koberle, 1999, Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours, Curr. Biol., 9, 273, 10.1016/S0960-9822(99)80118-3

Clugston, 1992, Binding of human single stranded DNA binding protein to DNA damaged by the anticancer drug cis-diamminedichloroplatinum(II), Cancer Res., 52, 6375

Patrick, 1999, Replication protein A (RPA) binding to duplex cisplatin-damaged DNA is mediated through the generation of single-stranded DNA, J. Biol. Chem., 274, 14972, 10.1074/jbc.274.21.14972

Matsunaga, 1996, Replication protein A confers structure-specific endonuclease activities to the XPF–ERCC1 and XPG subunits of human DNA repair excision nuclease, J. Biol. Chem., 271, 11047, 10.1074/jbc.271.19.11047

Evans, 1997, Open complex formation around a lesion during nucleotide excision repair provides a structure for cleavage by human XPG protein, EMBO J., 16, 625, 10.1093/emboj/16.3.625

de Laat, 1998, DNA-binding polarity of human replication protein A positions nucleases in nucleotide excision repair, Genes Dev., 12, 2598, 10.1101/gad.12.16.2598

Bhattacharyya, 1994, Mutator phenotypes in human colorectal carcinoma cell lines, Proc. Natl. Acad. Sci. U.S.A., 91, 6319, 10.1073/pnas.91.14.6319

Drummond, 1995, Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells, Science, 268, 1909, 10.1126/science.7604264

Acharya, 1996, hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6, Proc. Natl. Acad. Sci. U.S.A., 93, 13629, 10.1073/pnas.93.24.13629

Marsischky, 1996, Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair, Genes Dev., 10, 407, 10.1101/gad.10.4.407

Palombo, 1996, hMutSβ, a heterodimer of hMSH2 and hMSH3, binds to insertion/deletion loops in DNA, Curr. Biol., 6, 1181, 10.1016/S0960-9822(02)70685-4

Mello, 1996, The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin, Chem. Biol., 3, 579, 10.1016/S1074-5521(96)90149-0

Duckett, 1996, Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, Proc. Natl. Acad. Sci. U.S.A., 93, 6443, 10.1073/pnas.93.13.6443

Mu, 1997, Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems, Mol. Cell Biol., 17, 760, 10.1128/MCB.17.2.760

Yamada, 1997, Selective recognition of a cisplatin–DNA adduct by human mismatch repair proteins, Nucl. Acids Res., 25, 491, 10.1093/nar/25.3.491

Anthoney, 1996, Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells, Cancer Res., 56, 1374

Aebi, 1996, Loss of DNA mismatch repair in acquired resistance to cisplatin, Cancer Res., 56, 3087

Drummond, 1996, Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line, J. Biol. Chem., 271, 19645, 10.1074/jbc.271.33.19645

Brown, 1997, hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents, Oncogene, 15, 45, 10.1038/sj.onc.1201167

Fink, 1996, The role of DNA mismatch repair in platinum drug resistance, Cancer Res., 56, 4881

Vaisman, 1998, The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum–DNA adducts, Cancer Res., 58, 3579

Fink, 1997, In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair, Cancer Res., 57, 1841

Reitmair, 1997, Mutator phenotype in Msh2-deficient murine embryonic fibroblasts, Cancer Res., 57, 3765

Goldmacher, 1986, Isolation and partial characterization of human cell mutants differing in sensitivity to killing and mutation by methylnitrosourea and N-methyl-N′-nitro-N-nitrosoguanidine, J. Biol. Chem., 261, 12462, 10.1016/S0021-9258(18)67110-8

Hawn, 1995, Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint, Cancer Res., 55, 3721

Brown, 1997, hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents, Oncogene, 15, 45, 10.1038/sj.onc.1201167

Nehme, 1997, Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin, Cancer Res., 57, 3253

Nehme, 1999, Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells, Brit. J. Cancer, 79, 1104, 10.1038/sj.bjc.6690176

Gong, 1999, The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage, Nature, 399, 806, 10.1038/21690

Moggs, 1997, Differential human nucleotide excision repair of paired and mispaired cisplatin–DNA adducts, Nucl. Acids Res., 25, 480, 10.1093/nar/25.3.480

Wyatt, 1999, 3-Methyladenine DNA glycosylases: structure, function, and biological importance, BioEssays, 21, 668, 10.1002/(SICI)1521-1878(199908)21:8<668::AID-BIES6>3.0.CO;2-D

Kartalou, 2000, Cisplatin adducts inhibit 1,N6-ethenoadenine repair by interacting with the human 3-methyladenine DNA glycosylase, Biochemistry, 39, 8032, 10.1021/bi000417h

Miao, 2000, 3-Methyladenine–DNA glycosylase (MPG protein) interacts with human RAD23 proteins, J. Biol. Chem., 275, 28433, 10.1074/jbc.M001064200

Murchie, 1993, T4 endonuclease VII cleaves DNA containing a cisplatin adduct, J. Mol. Biol., 233, 77, 10.1006/jmbi.1993.1486

Muller, 1998, UV sensitivity and impaired nucleotide excision repair in DNA-dependent protein kinase mutant cells, Nucl. Acids Res., 26, 1382, 10.1093/nar/26.6.1382

Frit, 1999, Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis-dichlorodiammineplatinum(II): role of Ku autoantigen, Mol. Pharmacol., 56, 141, 10.1124/mol.56.1.141

Turchi, 1996, Human Ku autoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinase, J. Biol. Chem., 271, 13861, 10.1074/jbc.271.23.13861

Turchi, 1997, Mechanism of DNA-dependent protein kinase inhibition by cis-diamminedichloroplatinum(II)-damaged DNA, Biochemistry, 36, 7586, 10.1021/bi963124q

Turchi, 1999, Interactions of mammalian proteins with cisplatin-damaged DNA, J. Inorg. Biochem., 77, 83, 10.1016/S0162-0134(99)00145-2

Dolling, 1998, Modulation of radiation-induced strand break repair by cisplatin in mammalian cells, Int. J. Radiat. Biol., 74, 61, 10.1080/095530098141735